Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO)

Publication | Closed Access

DOI

Citations

References

2017

Year

Salah‐Eddin Al‐Batran, Claudia Pauligk, Nils Homann, Harald Schmalenberg, Hans‐Georg Kopp, Georg Martin Haag, Barbara Luley Kim, H. S. Wolff, Gunnar Folprecht, Stephan Probst,

Annals of Oncology

Flot4 TrialSurgical OncologyEsophagusEsophageal CancerGastrointestinal OncologyMedicineGerman Gastric GroupGastroenterologySurgeryOncologyRadiation OncologyEsophageal SurgeryCancer ResearchPhase 3